Sinovac Biotech Ltd. SVA announced today the unblinded results of its Phase I clinical trial for its proprietary inactivated vaccine against human enterovirus 71, which causes Hand, Foot, and Mouth Disease.
The safety observation results for the EV71 vaccine for all three age groups showed good safety and tolerance profiles and the preliminary immunogenicity study results showed the vaccines can induce good immune responses.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in